Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 3/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496928 | 1.00 | ATR (0.40) | ATRALDH1A1SMN1; SMN2PARP1RXFP1 | |
| SCHEMBL4494447 | 0.95 | BRD4 (0.38) | ATRALDH1A1SMN1; SMN2RXFP1PLK1 | |
| SCHEMBL4494450 | 0.95 | BRD4 (0.38) | ATRALDH1A1SMN1; SMN2RXFP1PLK1 | |
| SCHEMBL4490897 | 0.92 | TDP1 (0.38) | ATRALDH1A1RXFP1HRH4ADORA2A | |
| SCHEMBL4490893 | 0.92 | TDP1 (0.38) | ATRALDH1A1RXFP1HRH4ADORA2A | |
| SCHEMBL4481674 | 0.89 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2PARP1RXFP1PLK1 | |
| SCHEMBL4481672 | 0.89 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2PARP1RXFP1PLK1 | |
| SCHEMBL3848089 | 0.88 | RAB9A (0.42) | ATRALDH1A1SMN1; SMN2ADORA2AADORA1 | |
| SCHEMBL4493210 | 0.87 | EGLN1 (0.41) | ATRALDH1A1SMN1; SMN2PARP1ADORA2A | |
| SCHEMBL4493214 | 0.87 | EGLN1 (0.41) | ATRALDH1A1SMN1; SMN2PARP1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | ATR 526/4885ALDH1A1 2036/4885SMN1; SMN2 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.